Page last updated: 2024-11-04

vorinostat and Cutaneous T-Cell Lymphoma

vorinostat has been researched along with Cutaneous T-Cell Lymphoma in 54 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research Excerpts

ExcerptRelevanceReference
"Mogamulizumab significantly prolonged progression-free survival compared with vorinostat, and could provide a new, effective treatment for patients with mycosis fungoides and, importantly, for Sézary syndrome, a subtype that represents a major therapeutic challenge in cutaneous T-cell lymphoma."9.27Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. ( Bagot, M; Dalle, S; Duvic, M; Dwyer, K; Elmets, C; Eradat, H; Fierro, MT; Fisher, DC; Geskin, LJ; Grebennik, DO; Greer, J; Halwani, A; Horwitz, SM; Hudgens, S; Humphrey, JS; Khot, A; Kim, EJ; Kim, YH; Leoni, M; Moriya, J; Morris, S; Moskowitz, AJ; Musiek, A; Ortiz-Romero, PL; Pinter-Brown, L; Poligone, B; Porcu, P; Pro, B; Rook, AH; Scarisbrick, J; Shustov, A; Sokol, L; Tobinai, K; Tokura, Y; Tsianakas, A; Vermeer, M; Whittaker, S; Zinzani, PL, 2018)
"The retinoid X receptor (RXR)-agonist bexarotene and the histone deacetylase inhibitor (HDACI) vorinostat are each established monotherapies for cutaneous T-cell lymphomas (CTCLs)."9.16Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. ( Ahern, JD; Assaf, C; Baumann, K; Bernards, R; Beyer, M; Dummer, R; Epping, MT; Frankel, SR; Garcia-Vargas, J; Hardwick, JS; Heath, K; Hymes, K; Kerl, H; Rizvi, S; Steinhoff, M; Sterry, W; Whittaker, SJ, 2012)
"A phase I study was conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of the oral histone deacetylase (HDAC) inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL)."9.16Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma. ( Hamada, T; Iwatsuki, K; Kato, Y; Noguchi, K; Shimamoto, T; Sugaya, M; Tobinai, K; Tsuboi, R; Wada, H, 2012)
"Vorinostat, an orally active histone deacetylase inhibitor, was approved in October 2006 by the US Food and Drug Administration for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease during or after treatment with 2 systemic therapies."9.14Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. ( Abuav, R; Boileau, K; Breneman, D; Chen, C; Duvic, M; Geskin, LJ; Gunchenko, A; Olsen, EA; Pacheco, TR; Parker, S; Ricker, JL; Rizvi, S; Sanz-Rodriguez, C; Vonderheid, EC, 2009)
"The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL)."9.12Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). ( Chiao, JH; Duvic, M; Frankel, SR; Hazarika, P; Kelly, C; Ni, X; Reilly, JF; Richon, VM; Ricker, JL; Talpur, R; Zhang, C, 2007)
"To evaluate the activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in persistent, progressive, or recurrent mycosis fungoides or Sézary syndrome (MF/SS) cutaneous t-cell lymphoma (CTCL) subtypes."9.12Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. ( Arduino, JM; Chen, C; Duvic, M; Foss, FM; Frankel, SR; Kim, YH; Kuzel, TM; Olsen, EA; Pacheco, TR; Parker, S; Ricker, JL, 2007)
" The Food and Drug Administration has approved two HDAC inhibitors, vorinostat (2006) and romidepsin (2009), for the treatment of cutaneous T-cell lymphoma."8.93The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies. ( Dimopoulos, M; Duvic, M, 2016)
"The pharmacology, pharmacokinetics, clinical efficacy, safety, adverse effects, dosage and administration, and role in therapy of vorinostat in the treatment of cutaneous T-cell lymphoma (CTCL) are reviewed."8.86Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. ( Kavanaugh, SA; Kavanaugh, SM; Kolesar, JM; White, LA, 2010)
" Vorinostat (suberoylanilide hydroxamic acid) is the first FDA-approved HDAC inhibitor for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL)."8.84Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. ( Duvic, M; Vu, J, 2007)
"Vorinostat and romidepsin are histone deacetylase inhibitors (HDI), approved for the treatment of cutaneous T-cell lymphoma (CTCL)."7.77The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. ( Adams, J; Ganesan, A; Hodges, E; Packham, G; Tiffon, C; Townsend, P; van der Fits, L; Vermeer, M; Wen, S, 2011)
"Vorinostat (suberoylanilide hydroxamic acid, SAHA), an inhibitor of class I and II histone deacetylases, has been approved for the treatment of cutaneous T-cell lymphoma."7.76Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. ( Aparicio, CB; Bischoff, JR; de La Cueva, P; Herrera, M; Herreros, B; Longo, MI; Martin-Perez, D; Martínez Leal, JF; Ortiz-Romero, PL; Piris, MA; Rodriguez, ME; Villuendas, R; Wozniak, MB, 2010)
"To discuss vorinostat approval for treatment of cutaneous manifestations of advanced cutaneous T-cell lymphoma (CTCL)."7.74Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. ( Abraham, S; Booth, BP; Dagher, R; Farrell, A; Harapanhalli, RS; He, K; Jee, JM; Johnson, JR; Justice, R; Mann, BS; Morse, DE; Pazdur, R; Pope, S; Sridhara, R; Verbois, L, 2007)
"Vorinostat was active against solid tumors and hematologic malignancies as intravenous and oral preparations in phase I development."6.44Vorinostat in cutaneous T-cell lymphoma. ( Duvic, M; Vu, J, 2007)
"Mogamulizumab significantly prolonged progression-free survival compared with vorinostat, and could provide a new, effective treatment for patients with mycosis fungoides and, importantly, for Sézary syndrome, a subtype that represents a major therapeutic challenge in cutaneous T-cell lymphoma."5.27Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. ( Bagot, M; Dalle, S; Duvic, M; Dwyer, K; Elmets, C; Eradat, H; Fierro, MT; Fisher, DC; Geskin, LJ; Grebennik, DO; Greer, J; Halwani, A; Horwitz, SM; Hudgens, S; Humphrey, JS; Khot, A; Kim, EJ; Kim, YH; Leoni, M; Moriya, J; Morris, S; Moskowitz, AJ; Musiek, A; Ortiz-Romero, PL; Pinter-Brown, L; Poligone, B; Porcu, P; Pro, B; Rook, AH; Scarisbrick, J; Shustov, A; Sokol, L; Tobinai, K; Tokura, Y; Tsianakas, A; Vermeer, M; Whittaker, S; Zinzani, PL, 2018)
"The retinoid X receptor (RXR)-agonist bexarotene and the histone deacetylase inhibitor (HDACI) vorinostat are each established monotherapies for cutaneous T-cell lymphomas (CTCLs)."5.16Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. ( Ahern, JD; Assaf, C; Baumann, K; Bernards, R; Beyer, M; Dummer, R; Epping, MT; Frankel, SR; Garcia-Vargas, J; Hardwick, JS; Heath, K; Hymes, K; Kerl, H; Rizvi, S; Steinhoff, M; Sterry, W; Whittaker, SJ, 2012)
"A phase I study was conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of the oral histone deacetylase (HDAC) inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL)."5.16Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma. ( Hamada, T; Iwatsuki, K; Kato, Y; Noguchi, K; Shimamoto, T; Sugaya, M; Tobinai, K; Tsuboi, R; Wada, H, 2012)
"Vorinostat, an orally active histone deacetylase inhibitor, was approved in October 2006 by the US Food and Drug Administration for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease during or after treatment with 2 systemic therapies."5.14Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. ( Abuav, R; Boileau, K; Breneman, D; Chen, C; Duvic, M; Geskin, LJ; Gunchenko, A; Olsen, EA; Pacheco, TR; Parker, S; Ricker, JL; Rizvi, S; Sanz-Rodriguez, C; Vonderheid, EC, 2009)
"The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL)."5.12Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). ( Chiao, JH; Duvic, M; Frankel, SR; Hazarika, P; Kelly, C; Ni, X; Reilly, JF; Richon, VM; Ricker, JL; Talpur, R; Zhang, C, 2007)
"To evaluate the activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in persistent, progressive, or recurrent mycosis fungoides or Sézary syndrome (MF/SS) cutaneous t-cell lymphoma (CTCL) subtypes."5.12Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. ( Arduino, JM; Chen, C; Duvic, M; Foss, FM; Frankel, SR; Kim, YH; Kuzel, TM; Olsen, EA; Pacheco, TR; Parker, S; Ricker, JL, 2007)
" The Food and Drug Administration has approved two HDAC inhibitors, vorinostat (2006) and romidepsin (2009), for the treatment of cutaneous T-cell lymphoma."4.93The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies. ( Dimopoulos, M; Duvic, M, 2016)
" Food and Drug Administration, vorinostat and romidepsin, both with indications for cutaneous T-cell lymphoma."4.89Histone deacetylase inhibitors: novel agents in cancer treatment. ( Glass, E; Viale, PH, 2013)
" The hydroxamic acid derivative SAHA (also known as vorinostat or Zolinza®) and the cyclic depsipeptide FK228 (romidepsin or Istodax®) have gained approval from the US FDA for the treatment of cutaneous T-cell lymphoma."4.88Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications. ( Thaler, F, 2012)
"Vorinostat is a histone deacetylase inhibitor used in the treatment of recurrent or persistent cases of cutaneous T-cell lymphoma (CTCL)."4.88QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature. ( Lynch, DR; Newby, LK; Washam, JB, 2012)
"The pharmacology, pharmacokinetics, clinical efficacy, safety, adverse effects, dosage and administration, and role in therapy of vorinostat in the treatment of cutaneous T-cell lymphoma (CTCL) are reviewed."4.86Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. ( Kavanaugh, SA; Kavanaugh, SM; Kolesar, JM; White, LA, 2010)
" Hematological malignancies seem to be particularly sensitive, and vorinostat (also called suberoylanilide hydroxamic acid) has recently been approved for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients with progressive, persistent or recurrent disease."4.84Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. ( Khan, O; La Thangue, NB, 2008)
" Vorinostat (suberoylanilide hydroxamic acid) is the first FDA-approved HDAC inhibitor for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL)."4.84Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. ( Duvic, M; Vu, J, 2007)
"Vorinostat and romidepsin are histone deacetylase inhibitors (HDI), approved for the treatment of cutaneous T-cell lymphoma (CTCL)."3.77The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. ( Adams, J; Ganesan, A; Hodges, E; Packham, G; Tiffon, C; Townsend, P; van der Fits, L; Vermeer, M; Wen, S, 2011)
"Vorinostat (suberoylanilide hydroxamic acid, SAHA), an inhibitor of class I and II histone deacetylases, has been approved for the treatment of cutaneous T-cell lymphoma."3.76Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. ( Aparicio, CB; Bischoff, JR; de La Cueva, P; Herrera, M; Herreros, B; Longo, MI; Martin-Perez, D; Martínez Leal, JF; Ortiz-Romero, PL; Piris, MA; Rodriguez, ME; Villuendas, R; Wozniak, MB, 2010)
"To discuss vorinostat approval for treatment of cutaneous manifestations of advanced cutaneous T-cell lymphoma (CTCL)."3.74Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. ( Abraham, S; Booth, BP; Dagher, R; Farrell, A; Harapanhalli, RS; He, K; Jee, JM; Johnson, JR; Justice, R; Mann, BS; Morse, DE; Pazdur, R; Pope, S; Sridhara, R; Verbois, L, 2007)
"Vorinostat is a histone deacetylase inhibitor that has demonstrated preclinical activity in numerous cancer models."2.49Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. ( Agrawal, NG; Friedman, EJ; Iwamoto, M; Rubin, EH; Sandhu, P; Wagner, JA, 2013)
"Vorinostat was approved in the United States in 2006 for the treatment of cutaneous manifestations of T-cell lymphoma in patients with progressive, persistent, or recurrent disease on or following 2 systemic therapies."2.46The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma. ( Hymes, KB, 2010)
"Vorinostat was active against solid tumors and hematologic malignancies as intravenous and oral preparations in phase I development."2.44Vorinostat in cutaneous T-cell lymphoma. ( Duvic, M; Vu, J, 2007)
"This study was conducted to identify novel therapeutic targets that can be combined with HDACis for treating CTCL."1.62Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma. ( Fujii, K; Jimura, N; Kanekura, T; Kondo, T; Qiao, Z; Tsuchiya, R; Yoshimatsu, Y, 2021)
"Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL)."1.42Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. ( Benoit, BM; Cedeno-Laurent, F; Kim, EJ; Rook, AH; Singer, EM; Vittorio, CC; Wysocka, M; Yosipovitch, G, 2015)
" The extreme photopotency of UVASens allows the use of lower radiation doses minimising the carcinogenic risks associated with the long-term use of phototherapy."1.40Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells. ( Karagiannis, TC; Sung, JJ; Ververis, K, 2014)

Research

Studies (54)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's17 (31.48)29.6817
2010's31 (57.41)24.3611
2020's6 (11.11)2.80

Authors

AuthorsStudies
Fournier, JF1
Bhurruth-Alcor, Y1
Musicki, B1
Aubert, J1
Aurelly, M1
Bouix-Peter, C1
Bouquet, K1
Chantalat, L1
Delorme, M1
Drean, B1
Duvert, G1
Fleury-Bregeot, N1
Gauthier, B1
Grisendi, K1
Harris, CS1
Hennequin, LF1
Isabet, T1
Joly, F1
Lafitte, G1
Millois, C1
Morgentin, R1
Pascau, J1
Piwnica, D1
Rival, Y1
Soulet, C1
Thoreau, É1
Tomas, L1
Fujii, K2
Idogawa, M1
Suzuki, N1
Iwatsuki, K2
Kanekura, T2
Beylot-Barry, M1
Booken, N1
Weishaupt, C1
Scarisbrick, J3
Wu, W1
Rosen, JP1
Medley, MC1
Papadopoulou, V1
Degrauwe, N1
Decosterd, LA1
Buclin, T1
Cairoli, A1
Bordeaux, ZA1
Reddy, SV1
Lee, K1
Lu, W1
Choi, J1
Miller, M1
Roberts, C1
Pollizzi, A1
Kwatra, SG1
Kwatra, MM1
Ikumi, N1
Fujita, H1
Terui, T1
Takahashi, H1
Miura, K1
Hatta, Y1
Takei, M1
Jimura, N1
Qiao, Z1
Tsuchiya, R1
Yoshimatsu, Y1
Kondo, T1
Horwitz, S1
Zinzani, PL2
Bagot, M2
Kim, YH3
Moskowitz, AJ2
Porcu, P2
Dwyer, K2
Sun, W1
Herr, FM1
Kießling, MK1
Nicolay, JP1
Schlör, T1
Klemke, CD1
Süss, D1
Krammer, PH1
Gülow, K1
Cyrenne, BM1
Lewis, JM1
Weed, JG1
Carlson, KR1
Mirza, FN1
Foss, FM2
Girardi, M1
Geskin, L1
Malone, DC1
Gniadecki, R1
Pinter-Brown, L1
Rook, AH3
Horwitz, SM1
Whittaker, S1
Tokura, Y1
Vermeer, M2
Sokol, L1
Morris, S1
Kim, EJ3
Ortiz-Romero, PL2
Eradat, H1
Tsianakas, A1
Elmets, C1
Dalle, S1
Fisher, DC1
Halwani, A1
Poligone, B1
Greer, J1
Fierro, MT1
Khot, A1
Musiek, A1
Shustov, A1
Pro, B1
Geskin, LJ2
Moriya, J1
Leoni, M1
Humphrey, JS1
Hudgens, S1
Grebennik, DO1
Tobinai, K2
Duvic, M10
Iwamoto, M1
Friedman, EJ1
Sandhu, P1
Agrawal, NG1
Rubin, EH1
Wagner, JA1
Thaler, F1
Nihal, M1
Ahmad, N1
Wood, GS1
Sung, JJ1
Ververis, K1
Karagiannis, TC1
Litvinov, IV1
Cordeiro, B1
Fredholm, S1
Ødum, N1
Zargham, H1
Huang, Y1
Zhou, Y1
Pehr, K1
Kupper, TS1
Woetmann, A2
Sasseville, D1
Cedeno-Laurent, F1
Singer, EM1
Wysocka, M1
Benoit, BM1
Vittorio, CC2
Yosipovitch, G1
Kitadate, A2
Ikeda, S2
Teshima, K2
Ito, M1
Toyota, I1
Hasunuma, N1
Takahashi, N2
Miyagaki, T2
Sugaya, M3
Tagawa, H2
Dimopoulos, M1
Abe, F1
Yamashita, J1
Nakanishi, H1
Asaka, C1
Heymann, WR1
Khan, O1
La Thangue, NB1
Heider, U1
Rademacher, J1
Lamottke, B1
Mieth, M1
Moebs, M1
von Metzler, I1
Assaf, C2
Sezer, O1
Gardner, JM1
Evans, KG1
Goldstein, S1
Olsen, EA2
Breneman, D1
Pacheco, TR2
Parker, S2
Vonderheid, EC1
Abuav, R1
Ricker, JL3
Rizvi, S2
Chen, C2
Boileau, K1
Gunchenko, A1
Sanz-Rodriguez, C1
Wozniak, MB1
Villuendas, R1
Bischoff, JR1
Aparicio, CB1
Martínez Leal, JF1
de La Cueva, P1
Rodriguez, ME1
Herreros, B1
Martin-Perez, D1
Longo, MI1
Herrera, M1
Piris, MA1
Hymes, KB1
Zirlik, K1
Nashan, D1
Veelken, H1
Kavanaugh, SM1
Kavanaugh, SA1
White, LA1
Kolesar, JM1
Krejsgaard, T1
Kopp, K1
Ralfkiaer, E1
Willumsgaard, AE1
Eriksen, KW1
Labuda, T1
Rasmussen, S1
Mathiesen, AM1
Geisler, C1
Lauenborg, B1
Becker, JC1
Zhang, Q1
Wasik, MA1
Odum, N1
Zain, J1
Kaminetzky, D1
O'Connor, OA1
Tiffon, C1
Adams, J1
van der Fits, L1
Wen, S1
Townsend, P1
Ganesan, A1
Hodges, E1
Packham, G1
Dummer, R1
Beyer, M1
Hymes, K1
Epping, MT1
Bernards, R1
Steinhoff, M1
Sterry, W2
Kerl, H1
Heath, K1
Ahern, JD1
Hardwick, JS1
Garcia-Vargas, J1
Baumann, K1
Frankel, SR3
Whittaker, SJ1
Wada, H1
Tsuboi, R1
Kato, Y1
Hamada, T1
Shimamoto, T1
Noguchi, K1
Al-Yacoub, N1
Fecker, LF1
Möbs, M1
Plötz, M1
Braun, FK1
Eberle, J1
Lynch, DR1
Washam, JB1
Newby, LK1
Giannini, G1
Cabri, W1
Fattorusso, C1
Rodriquez, M1
Marks, P1
Glass, E1
Viale, PH1
Zhang, C2
Richon, V1
Ni, X2
Talpur, R2
Hazarika, P1
Kelly, C1
Chiao, JH1
Reilly, JF1
Richon, VM1
Thompson, CA1
Grant, S1
Easley, C1
Kirkpatrick, P1
Mann, BS2
Johnson, JR2
He, K1
Sridhara, R1
Abraham, S1
Booth, BP1
Verbois, L1
Morse, DE1
Jee, JM1
Pope, S1
Harapanhalli, RS1
Dagher, R1
Farrell, A1
Justice, R2
Pazdur, R2
Kuzel, TM1
Arduino, JM1
Vu, J2
Scheinfeld, N1
Cohen, MH1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma[NCT01728805]Phase 3372 participants (Actual)Interventional2012-11-30Completed
Phase II Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma[NCT05996185]Phase 236 participants (Anticipated)Interventional2024-01-31Not yet recruiting
A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers[NCT00907738]Phase 227 participants (Actual)Interventional2005-08-31Completed
A Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat; Zolinza) in Combination With Bexarotene in Patients With Advanced Cutaneous T-Cell Lymphoma[NCT00127101]Phase 123 participants (Actual)Interventional2005-09-30Terminated (stopped due to The study was stopped due to low enrollment.)
Phase I Clinical Study of MK-0683 in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL)[NCT00771472]Phase 110 participants (Actual)Interventional2008-08-31Completed
Phase IIb Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Advanced Cutaneous T-cell Lymphoma[NCT00091559]Phase 274 participants (Actual)Interventional2005-02-03Completed
A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer[NCT01045538]Phase 1/Phase 245 participants (Actual)Interventional2010-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Pruritis Evaluation

"The Itchy QoL is a validated pruritus specific quality of life instrument. It includes 22 pruritus-specific questions covering three major domains: symptoms, functioning, and emotions. The scale ranges from Never (1) to All The Time (5). The subscale scores consist of the average of the responses to the items in a given subscale. The overall score is the average of the responses to all items. Higher Itchy QoL scores indicate worse quality of life.~LS mean (and 95% CI) of the overall change from baseline across time points through 6-month assessment (including End of Cycles 1, 3, and 5 time points only) are calculated from MMRM with treatment, disease type, disease stage, and region as fixed effects and baseline score as a covariate." (NCT01728805)
Timeframe: Cycle 1, 3, and 5

Interventionscore on a scale (Least Squares Mean)
KW-0761-0.5
Vorinostat-0.4

Overall Response Rate

The ORR was defined as the count of subjects who had a confirmed CR or PR, defined as documented CR or PR per Global Composite Response Score that was confirmed by a subsequent observation at least 4 weeks later. Overall Response Rate was determined based on the response in all compartments (lymph nodes, skin, peripheral blood, and viscera), referencing Olsen, 2011 as follows: Complete Response (CR) = complete disappearance of all clinical evidence of disease; Partial Response (PR) = regression of measurable disease; Stable Disease (SD) = failure to attain CR, PR, or PD; Progressive Disease (PD) = PD in any compartment; Relapse = recurrence of disease in prior CR in any compartment. (NCT01728805)
Timeframe: at the end of cycle 1 (26-28 days), and then every other cycle in Year 1 (cycle 3, 5, 7, 9, 11, 13), and every 16 weeks (cycle 17, 21, etc.) in Year 2 and beyond until progression up to 36 months

,
InterventionParticipants (Count of Participants)
All Subjects ORR (confirmed CR + PR)Disease Type = MF ORR (confirmed CR + PR)Disease Type = SS ORR (confirmed CR + PR)
KW-0761522230
Vorinostat972

Progression Free Survival

"Progression was defined as follows, based on Olsen (2011):~Lymph nodes: ≥ 50% increase in SPD from baseline of lymph nodes, any new node > 1.5 cm in the long axis or > 1 cm in the short axis if 1-1.5 cm in the long axis that is proven to be N3 histologically, or > 50% increase from nadir in SPD of lymph nodes in those with PR~Skin: ≥ 25% increase in skin disease from baseline, new tumors (T3) in patients with T1, T2 or T4 only skin disease, or in those with CR or PR, increase of skin score of greater than the sum of nadir plus 50% baseline score~Blood: B0 to B2, > 50% increase from baseline and at least 5,000 neoplastic cells/μL36, or > 50% increase from nadir and at least 5,000 neoplastic cells/μL~Viscera: > 50% increase in size (SPD) of any organs involved at baseline, new organ involvement, or > 50% increase from nadir in the size (SPD) of any previous organ involvement in those with PR" (NCT01728805)
Timeframe: From date of randomization at every visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months

,
Interventionpercentage of subjects (Number)
Rate (%) of Being Alive w/o Progression at 6 mos.Rate (%) of Being Alive w/o Progression at 12 mos.Rate (%) of Being Alive w/o Progression at 18 mos.Rate (%) of Being Alive w/o Progression at 24 mos.Rate (%) of Being Alive w/o Progression at 30 mos.
KW-076155.338.328.014.14.7
Vorinostat28.815.37.27.27.2

Quality of Life (QoL) Assessment - Skindex-29 Symptoms Scale Score

"Skindex-29 rates 29 items assessing 3 domains (emotions, symptoms, & functioning) on a linear scale from 0 (never) to all the time (100). Higher scores = higher impact of skin disease.~FACT-G rates 27 items in 4 domains (physical well-being, social/family well-being, emotional well-being, functional well-being) on a 5-point scale from 0 (not at all) to 4 (very much). Higher scores = better QoL.~EuroQoL lvl 3 (Eq-5D-3L) rates mobility, self-care, usual activities, pain/discomfort and anxiety/depression on 3 levels - no problems, some problems, extreme problems. Score is calculated using a set of item weights to derive a single score ranging from -0.109 to 1, with 1 representing full health.~LS mean (and 95% CI) of the overall change from baseline across time points through 6-month assessment (including End of Cycles 1, 3, and 5 time points only) are calculated from MMRM with treatment, disease type, disease stage, and region as fixed effects and baseline score as a covariate." (NCT01728805)
Timeframe: Cycle 1, 3, and 5

,
Interventionscore on a scale (Least Squares Mean)
Skindex-29 Across 6-month AssessmentFACT-G Across 6-month AssessmentEQ-5D-3L Across 6-month Assessment
KW-0761-12.64.60.06
Vorinostat-6.0-2.30.02

Percent of Participants With a Serious Drug-related Adverse Event (AE)

"A serious adverse event (SAE) was any AE occurring at any dose that resulted in death, was life-threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was a cancer, or was an overdose.~A drug-related SAE was one that was thought to be possibly, probably, or definitely related to the study drug." (NCT00907738)
Timeframe: From the first dose of study drug until the patient experiences disease progression, withdraws consent, or develops unacceptable toxicity (from Day 1 up to 4 years and 9 months)

Interventionpercent of participants (Number)
Base Protocol 0017.7
Base Protocol 0060
Base Protocol 0080
Base Protocol 0120
Base Protocol 0130

Maximum Tolerated Dose (MTD) as Determined by the Number of Participants With Dose Limiting Toxicities

Number of patients with Dose Limiting Toxicities (DLT). A DLT is an adverse event that determined the treatment dose level was not tolerable for that patient in Cycle 1. (NCT00127101)
Timeframe: Day 1 to day 28

,,,,,
InterventionParticipants (Number)
DLTNo DLT
Cohort 103
Cohort 223
Cohort 2a03
Cohort 2b03
Cohort 605
Cohort 712

Number of Participants Who Responded to Treatment

"Disease burden as assessed by the pre-specified Severity Weighted Assessment Tool (SWAT) measurement. A Response is defined as equal to or greater than 50% improvement in SWAT score.~SWAT Score is determined by the Lesions classified as patch, plaque, or tumor. The sum of percent of total body surface area (%TBSA) by lesion type is derived and multiplied by a factor of 1 (for patch), 2 (for plaque), or 4 (for tumor). The skin score total is derived by summing the skin score subtotals for patches, plaques and tumors. The skin score total is dimensionless and can range from 0 to 400" (NCT00127101)
Timeframe: Every 28 days for up to 6 Months of Treatment

,,,,,
InterventionParticipants (Number)
ResponseNo Response
Cohort 103
Cohort 205
Cohort 2a03
Cohort 2b12
Cohort 623
Cohort 712

Part I: Number of Participants Experiencing Dose Limiting Toxicity (DLT)

"A DLT was defined as any of the following (per Common Terminology Criteria for Adverse Events [CTCAE] version 3.0):~Grade 3 (severe)-4 (life-threatening) neutropenia with fever ≥ 38.5ºC~Grade 3-4 neutropenia with an infection requiring antibiotic or antifungal treatment~Grade 4 neutropenia lasting at least 5 days~Grade 4 thrombocytopenia~Other Grade 4 hematologic toxicity, including a decrease in hemoglobin, only at the discretion of the principal investigator~Grade 3 or 4 non-hematologic event, except which are manageable by supportive care or non-prohibited therapies" (NCT00771472)
Timeframe: Day 1 to Day 28

Interventionparticipants (Number)
Vorinostat1

Part I: Maximum Drug Concentration (Cmax)

"Blood samples taken as follows:~Day 1 & Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat." (NCT00771472)
Timeframe: Days 1 & 28 of Cycle 1

InterventionµM (Geometric Mean)
Day 1 (n=6)Day 28 (n=5)
Vorinostat0.831.17

Part I: The Amount of Time it Takes for the Drug Concentration to Decrease by Half (T1/2)

"Blood samples taken as follows:~Day 1 & Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat." (NCT00771472)
Timeframe: Days 1 & 28 of Cycle 1

Interventionhours (Geometric Mean)
Day 1 (n=5)Day 28 (n=4)
Vorinostat1.942.30

Part I: Time at Which Cmax Occurs (Tmax)

"Blood samples taken as follows:~Day 1 & Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat." (NCT00771472)
Timeframe: Days 1 & 28 of Cycle 1

Interventionhours (Median)
Day 1 (n=6)Day 28 (n=5)
Vorinostat2.913.73

Part I: Total Drug Exposure (Area Under the Concentration Curve, AUC[0-24 Hours])

"Blood samples taken as follows:~Day 1 & Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat." (NCT00771472)
Timeframe: Days 1 & 28 of Cycle 1

InterventionµM*hr (Geometric Mean)
Day 1 (n=6)Day 28 (n=5)
Vorinostat4.595.59

Parts I & II: Number of Participants Experiencing Clinical or Laboratory Adverse Experiences (AE)

A laboratory AE is defined as any unfavorable & unintended change in the chemistry of the body temporally associated with the use of study product, whether or not considered related to the use of the product. A clinical AE is defined similarly but also includes changes in structure or function of the body. (NCT00771472)
Timeframe: Day 1 up until 30 days post study completion or early termination (up to approximately 506 days)

Interventionparticipants (Number)
Clinical AEsLaboratory AEs
Vorinostat106

Reviews

17 reviews available for vorinostat and Cutaneous T-Cell Lymphoma

ArticleYear
Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:3

    Topics: Dose-Response Relationship, Drug; Drug Interactions; Histone Deacetylase Inhibitors; Humans; Hydroxa

2013
Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications.
    Pharmaceutical patent analyst, 2012, Volume: 1, Issue:1

    Topics: Animals; Antineoplastic Agents; Depsipeptides; Drug Approval; Histone Deacetylase Inhibitors; Histon

2012
Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
    Dermatologic clinics, 2015, Volume: 33, Issue:4

    Topics: Depsipeptides; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lymphoma, T-Cell,

2015
The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
    Cancer treatment reviews, 2016, Volume: 43

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Depsipeptides; Disease Management; Hematologic Neoplas

2016
Treatment of cutaneous T-cell lymphoma: focus on vorinostat.
    Journal of the American Academy of Dermatology, 2008, Volume: 59, Issue:4

    Topics: Antineoplastic Agents; Fatigue; Gastrointestinal Diseases; Histone Deacetylase Inhibitors; Humans; H

2008
Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas.
    Nature clinical practice. Oncology, 2008, Volume: 5, Issue:12

    Topics: Antineoplastic Agents; Histone Deacetylases; Humans; Hydroxamic Acids; Lymphoma, T-Cell, Cutaneous;

2008
The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:2

    Topics: Antineoplastic Agents; Depsipeptides; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Humans;

2010
[Vorinostat in the treatment of cutaneous T-cell lymphomas. Treatment with histone deacetylases inhibitors].
    Pharmazie in unserer Zeit, 2010, Volume: 39, Issue:3

    Topics: Antineoplastic Agents; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma, T-Cell, C

2010
Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2010, May-15, Volume: 67, Issue:10

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Histone Deacetylase Inhibitors; Humans; Hydroxamic

2010
Emerging role of epigenetic therapies in cutaneous T-cell  lymphomas.
    Expert review of hematology, 2010, Volume: 3, Issue:2

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Depsipeptides; Epigenesis, Genetic; Histone Deacety

2010
QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature.
    Cardiology journal, 2012, Volume: 19, Issue:4

    Topics: Antineoplastic Agents; Doxepin; Electrocardiography; Histone Deacetylase Inhibitors; Humans; Hydroxa

2012
Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.
    Future medicinal chemistry, 2012, Volume: 4, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Depsipeptides; Drug Design; Drug Therapy, Combination; Histone Dea

2012
Histone deacetylase inhibitors: novel agents in cancer treatment.
    Clinical journal of oncology nursing, 2013, Volume: 17, Issue:1

    Topics: Antineoplastic Agents; Depsipeptides; Education, Nursing, Continuing; Histone Deacetylase Inhibitors

2013
Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
    Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:2 Suppl 1

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antine

2007
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.
    Expert opinion on investigational drugs, 2007, Volume: 16, Issue:7

    Topics: Administration, Oral; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic

2007
A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development.
    Journal of drugs in dermatology : JDD, 2007, Volume: 6, Issue:7

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bexarotene; Diphtheria Toxin; Drug Approv

2007
Vorinostat in cutaneous T-cell lymphoma.
    Drugs of today (Barcelona, Spain : 1998), 2007, Volume: 43, Issue:9

    Topics: Animals; Antineoplastic Agents; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma,

2007

Trials

9 trials available for vorinostat and Cutaneous T-Cell Lymphoma

ArticleYear
Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2023, Volume: 37, Issue:2

    Topics: Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Sezary Syndrome; Skin Neoplasms; Vorinostat

2023
Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:13

    Topics: Antibodies, Monoclonal, Humanized; Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Sezary Sy

2021
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
    The Lancet. Oncology, 2018, Volume: 19, Issue:9

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Australia; Drug Admin

2018
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
    The Lancet. Oncology, 2018, Volume: 19, Issue:9

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Australia; Drug Admin

2018
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
    The Lancet. Oncology, 2018, Volume: 19, Issue:9

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Australia; Drug Admin

2018
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
    The Lancet. Oncology, 2018, Volume: 19, Issue:9

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Australia; Drug Admin

2018
Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
    Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:6

    Topics: Aged; Antineoplastic Agents; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymph

2009
Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cell Line, Tumor; Cell Surv

2012
Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.
    The Journal of dermatology, 2012, Volume: 39, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Asian People; Histone Deacetylase Inhibitors; Humans; Hydroxamic

2012
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
    Blood, 2007, Jan-01, Volume: 109, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dehydration; Disease Progression; Disease-Fre

2007
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jul-20, Volume: 25, Issue:21

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Confidence Intervals; Dose-Response Relationsh

2007
FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
    The oncologist, 2007, Volume: 12, Issue:10

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relations

2007

Other Studies

28 other studies available for vorinostat and Cutaneous T-Cell Lymphoma

ArticleYear
Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma.
    Bioorganic & medicinal chemistry letters, 2018, 09-15, Volume: 28, Issue:17

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Dose

2018
Functional Depletion of HSP72 by siRNA and Quercetin Enhances Vorinostat-Induced Apoptosis in an HSP72-Overexpressing Cutaneous T-Cell Lymphoma Cell Line, Hut78.
    International journal of molecular sciences, 2021, Oct-19, Volume: 22, Issue:20

    Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Gene

2021
Simultaneous kinetics of oral vorinostat in plasma and cerebrospinal fluid in a patient with cutaneous T-cell lymphoma with CNS involvement.
    International journal of clinical pharmacology and therapeutics, 2023, Volume: 61, Issue:6

    Topics: Antineoplastic Agents; Humans; Kinetics; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; Vorinostat

2023
Differential Response of Mycosis Fungoides Cells to Vorinostat.
    International journal of molecular sciences, 2023, Apr-29, Volume: 24, Issue:9

    Topics: Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Proteomics; Skin Neoplasms; Vorinostat

2023
Aggressive CD4-CD8-CD45RA+CCR10- Primary Cutaneous Peripheral T-cell Lymphoma, Not Otherwise Specified: A Case Report.
    Acta dermato-venereologica, 2019, Nov-01, Volume: 99, Issue:12

    Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; CD4 Antigens; CD8 Antigens; Disease Progression; Fat

2019
Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
    Journal of dermatological science, 2021, Volume: 101, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Depsipeptides; Drug Scr

2021
NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
    Oncotarget, 2017, Jul-11, Volume: 8, Issue:28

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor;

2017
Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
    Blood, 2017, 11-09, Volume: 130, Issue:19

    Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Depsipeptides; Drug Screening Assays, Ant

2017
An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma.
    The Journal of dermatological treatment, 2018, Volume: 29, Issue:5

    Topics: Antineoplastic Agents; Bexarotene; Cost-Benefit Analysis; Diphtheria Toxin; Humans; Hydroxamic Acids

2018
CCR4-targeted therapy in cutaneous T-cell lymphoma.
    The Lancet. Oncology, 2018, Volume: 19, Issue:9

    Topics: Antibodies, Monoclonal, Humanized; Humans; Lymphoma, T-Cell, Cutaneous; Receptors, CCR4; Vorinostat

2018
SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis.
    Cell cycle (Georgetown, Tex.), 2014, Volume: 13, Issue:4

    Topics: Acetanilides; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival;

2014
Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells.
    Journal of photochemistry and photobiology. B, Biology, 2014, Feb-05, Volume: 131

    Topics: Benzamides; Cell Death; Cell Survival; DNA Damage; DNA Repair; Histone Deacetylase Inhibitors; Human

2014
Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.
    Cell cycle (Georgetown, Tex.), 2014, Volume: 13, Issue:18

    Topics: Cell Line, Tumor; Depsipeptides; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques;

2014
Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities.
    Clinical immunology (Orlando, Fla.), 2015, Volume: 158, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Depsipeptides; Dexamethasone; Female; Histone Deacetylase Inhibitors

2015
MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
    Oncogene, 2016, 07-14, Volume: 35, Issue:28

    Topics: Animals; Apoptosis; Blotting, Western; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinas

2016
Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
    Oncotarget, 2017, Jan-31, Volume: 8, Issue:5

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Female; Gene Expression Regulation,

2017
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
    European journal of haematology, 2009, Volume: 82, Issue:6

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, D

2009
Vorinostat for the treatment of bullous pemphigoid in the setting of advanced, refractory cutaneous T-cell lymphoma.
    Archives of dermatology, 2009, Volume: 145, Issue:9

    Topics: Antibodies, Anti-Idiotypic; Antineoplastic Agents; Diagnosis, Differential; Dose-Response Relationsh

2009
Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.
    Haematologica, 2010, Volume: 95, Issue:4

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cell Proliferat

2010
A novel xenograft model of cutaneous T-cell lymphoma.
    Experimental dermatology, 2010, Volume: 19, Issue:12

    Topics: Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cell Transplantation; Disease Models, A

2010
The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
    British journal of pharmacology, 2011, Volume: 162, Issue:7

    Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Depsipeptides; Down-Regulation; Histone Deacetylase Inhibit

2011
Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is related to downregulation of c-FLIP and enhanced TRAIL signaling.
    The Journal of investigative dermatology, 2012, Volume: 132, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; CASP8 and FADD-Like Apoptosis Regulating Protein; Do

2012
A conversation with Paul Marks. Interview by Ushma S. Neill.
    The Journal of clinical investigation, 2012, Volume: 122, Issue:10

    Topics: Antineoplastic Agents; Cancer Care Facilities; Glucosephosphate Dehydrogenase Deficiency; Hematology

2012
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
    The Journal of investigative dermatology, 2005, Volume: 125, Issue:5

    Topics: Acetylation; Antineoplastic Agents; Apoptosis; Caspase 3; Caspases; Cell Line, Tumor; Cyclin-Depende

2005
Vorinostat approved for rare lymphoma.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2006, Nov-15, Volume: 63, Issue:22

    Topics: Antineoplastic Agents; Drug Approval; Drug Labeling; Enzyme Inhibitors; Histone Deacetylase Inhibito

2006
Vorinostat.
    Nature reviews. Drug discovery, 2007, Volume: 6, Issue:1

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Drug Approval; D

2007
Vorinostat (Zolinza) for cutaneous T-Cell lymphoma.
    The Medical letter on drugs and therapeutics, 2007, Mar-12, Volume: 49, Issue:1256

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Histone Deacetylase Inhibitors; Humans; Hydroxamic

2007
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Apr-15, Volume: 13, Issue:8

    Topics: Animals; Anticarcinogenic Agents; Cats; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II

2007